



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

JAN 13 1995

#13

Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fisher's Lane, Room 11-44
Rockville, MD 20857

Re: Albunex

FDA Docket No. 94E-0360

Dear Mr. Wilson:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 4,844,882 issued July 4, 1989. The application was filed on September 21, 1994, under Title II of Public Law 98 - 417, the Drug Price Competition and Patent Term Restoration Act of 1984.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination by your office on the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 USC § 156(d)(2)(A).

Gerald A. Dost
Gerald A. Dost
Special Program Examiner
Office of Special Programs
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

(703) 305-9285

cc: Freddie K. Park
Morrison & Foerster
755 Page Mill Road
Palo Alto, CA 94304